血清标记物联合检测对肝癌的临床诊断价值

摘要

目的：探讨血清标记物联合检测对肝癌患者的临床诊断价值。方法选取本院收治的56例原发性肝癌、32例肝病患者以及同期体检的34名健康者作为研究对象，检测血清中的癌胚抗原（CEA）、恶性肿瘤生长因子（TSGF）、谷氨酰转肽酶（GGT）、甲胎蛋白（AFP）以及岩藻糖苷酶（AFU）标记物。结果原发性肝癌患者的AFP、TSGF、AFU、GGT以及CEA等指标高于良性肝病和正常体检者（P<0.05）；联合检测的敏感性和特异性均高于单一检测（P<0.05）。结论联合检测血清标记物能够有效提高肝癌的诊断敏感性。%Objective To explore the clinical value in combined detection of the serum tumor markers on patients with hepatocellular carcinoma.Methods56 cases primary liver cancer of the hospitalized patients,32 cases of other liver diseases, and34 healthy persons were collected. Carcinoembryonic antigen (CEA), serum malignant tumor growth factor (TSGF), glutamate based transpeptidase (GGT), alpha fetoprotein (AFP)and fucosidase (AFU) were determined.Results Indexes AFP, TSGF, AFU, GGT and CEA in patients with primary liver cancer were higher than those with benign liver diseases and normal control (P<0.05). The sensitivity and specificity of combined detection were higher than those of the single test (P <0.05).Conclusion The combined detection of serum tumor markers of liver cancer can effectively improve the accuracy of diagnosis, and provide important basis for the differential diagnosis of hepatocellular carcinoma.